Kent E. Pryor

Stroke Treatment Academic Industry Roundtable X

Sean I. Savitz, Jean‐Claude Baron, Marc Fisher et al. · Stroke · 2019 · 192 citations

Medicine, Health Policy, Neurology +10

Top Priorities for Cerebroprotective Studies—A Paradigm Shift: Report From STAIR XI

Patrick D. Lyden, Alastair M. Buchan, Johannes Boltze et al. · Stroke · 2021 · 159 citations · Full text

Medicine, Neurology, Neuroscience +17

Final Results of the RHAPSODY Trial: A Multi‐Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A‐APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke

Patrick D. Lyden, Kent E. Pryor, Christopher S. Coffey et al. · Annals of Neurology · 2018 · 142 citations

Medicine, Pharmacology, Pharmacotherapy +17

The activated core approach to combinatorial chemistry: A selection of new core molecules

Kent E. Pryor, Gerald W. Shipps, David Skyler et al. · Tetrahedron · 1998 · 83 citations

Pharmacy, Chemistry, Medicinal Chemistry +13

Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers

Patrick D. Lyden, Howard Levy, Sara Weymer et al. · Current Pharmaceutical Design · 2014 · 64 citations

Medicine, Pharmacokinetics, Pharmacology +13